

Alcoholic Hepatitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/A998C8954640EN.html>

Date: May 2024

Pages: 129

Price: US\$ 6,499.00 (Single User License)

ID: A998C8954640EN

Abstracts

The 7 major alcoholic hepatitis markets reached a value of US\$ 1.9 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 3.1 Billion by 2034, exhibiting a growth rate (CAGR) of 4.37% during 2024-2034.

The alcoholic hepatitis market has been comprehensively analyzed in IMARC's new report titled "Alcoholic Hepatitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Alcoholic hepatitis is a liver disease that occurs as a result of long-term excessive alcohol consumption. The condition is characterized by inflammation and damage to the liver, which can cause a range of symptoms, including jaundice, abdominal pain and swelling, fever, nausea and vomiting, fatigue, loss of appetite, etc. In some cases, people with alcoholic hepatitis may also experience confusion, agitation, and other signs of alcohol withdrawal, such as tremors, seizures, delirium tremens, etc. The diagnosis of alcoholic hepatitis typically involves a combination of medical history, physical examination, laboratory examinations, and imaging studies. Blood tests can help identify liver damage and inflammation, as well as other conditions that may be contributing to the symptoms. Several imaging studies, including ultrasound, CT scans, MRI scans, etc., can provide detailed images of the liver and aid in revealing any abnormalities. In some cases, a liver biopsy may be necessary to confirm the diagnosis and guide treatment decisions.

The increasing prevalence of liver diseases on account of rising alcohol consumption is primarily driving the alcoholic hepatitis market. Besides this, the escalating utilization of corticosteroids, such as prednisolone and pentoxifylline, for reducing inflammation and improving liver function in severe cases of alcoholic hepatitis is further creating a positive outlook for the market. Moreover, the emerging popularity of non-invasive tests,

including elastography and magnetic resonance imaging (MRI), for monitoring liver function and disease progression is also bolstering the market growth. Additionally, several government bodies are introducing treatment and support programs, such as counseling and medication-assisted treatment, for people with alcohol use disorders, including those who have developed alcoholic hepatitis. This, in turn, is acting as another significant growth-inducing factor. Furthermore, the widespread adoption of transjugular intrahepatic portosystemic shunt (TIPS) procedure to treat complications related to alcoholic hepatitis, such as portal hypertension, is also propelling the market growth. Apart from this, numerous key players are making extensive investments in exploring novel treatments for alcoholic hepatitis, including stem cell therapy that involves transplanting stem cells into the liver to promote regeneration, which is expected to drive the alcoholic hepatitis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the alcoholic hepatitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for alcoholic hepatitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the alcoholic hepatitis market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the alcoholic hepatitis market
Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the alcoholic hepatitis market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current alcoholic hepatitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the alcoholic hepatitis market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the alcoholic hepatitis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the alcoholic hepatitis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of alcoholic hepatitis across the seven major markets?

What is the number of prevalent cases (2018-2034) of alcoholic hepatitis by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of alcoholic hepatitis by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with alcoholic hepatitis across the seven major markets?

What is the size of the alcoholic hepatitis patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of alcoholic hepatitis?

What will be the growth rate of patients across the seven major markets?

Alcoholic hepatitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for alcoholic hepatitis drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc.

related to the alcoholic hepatitis market?

What are the key regulatory events related to the alcoholic hepatitis market?

What is the structure of clinical trial landscape by status related to the alcoholic hepatitis market?

What is the structure of clinical trial landscape by phase related to the alcoholic hepatitis market?

What is the structure of clinical trial landscape by route of administration related to the alcoholic hepatitis market?

Contents

?1 Preface

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 ALCOHOLIC HEPATITIS - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 ALCOHOLIC HEPATITIS - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 ALCOHOLIC HEPATITIS - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Diagnosed Cases (2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Diagnosed Cases (2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Diagnosed Cases (2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Diagnosed Cases (2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Diagnosed Cases (2018-2034)
 - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Diagnosed Cases (2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Diagnosed Cases (2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (2018-2034)

8 ALCOHOLIC HEPATITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 ALCOHOLIC HEPATITIS - UNMET NEEDS

10 ALCOHOLIC HEPATITIS - KEY ENDPOINTS OF TREATMENT

11 ALCOHOLIC HEPATITIS - MARKETED PRODUCTS

- 11.1 List of Alcoholic Hepatitis Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Drug Name – Company Name
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 ALCOHOLIC HEPATITIS - PIPELINE DRUGS

12.1 List of Alcoholic Hepatitis Pipeline Drugs Across the Top 7 Markets

12.1.1 DUR 928 - DURECT Corporation

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

12.1.2 INT 787 - Intercept Pharmaceuticals

12.1.2.1 Drug Overview

12.1.2.2 Mechanism of Action

12.1.2.3 Clinical Trial Results

12.1.2.4 Safety and Efficacy

12.1.2.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. ALCOHOLIC HEPATITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. ALCOHOLIC HEPATITIS – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 ALCOHOLIC HEPATITIS - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Alcoholic Hepatitis - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Alcoholic Hepatitis - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

- 15.3.1 Alcoholic Hepatitis - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
- 15.3.2 Alcoholic Hepatitis - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
- 15.3.3 Alcoholic Hepatitis - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Alcoholic Hepatitis - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Alcoholic Hepatitis - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Alcoholic Hepatitis - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Alcoholic Hepatitis - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Alcoholic Hepatitis - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Alcoholic Hepatitis - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Alcoholic Hepatitis - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Alcoholic Hepatitis - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Alcoholic Hepatitis - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Alcoholic Hepatitis - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Alcoholic Hepatitis - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Alcoholic Hepatitis - Access and Reimbursement Overview

15.8 Market Scenario - Spain

15.8.1 Alcoholic Hepatitis - Market Size

15.8.1.1 Market Size (2018-2023)

15.8.1.2 Market Forecast (2024-2034)

15.8.2 Alcoholic Hepatitis - Market Size by Therapies

15.8.2.1 Market Size by Therapies (2018-2023)

15.8.2.2 Market Forecast by Therapies (2024-2034)

15.8.3 Alcoholic Hepatitis - Access and Reimbursement Overview

15.9 Market Scenario - Japan

15.9.1 Alcoholic Hepatitis - Market Size

15.9.1.1 Market Size (2018-2023)

15.9.1.2 Market Forecast (2024-2034)

15.9.2 Alcoholic Hepatitis - Market Size by Therapies

15.9.2.1 Market Size by Therapies (2018-2023)

15.9.2.2 Market Forecast by Therapies (2024-2034)

15.9.3 Alcoholic Hepatitis - Access and Reimbursement Overview

16 ALCOHOLIC HEPATITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 ALCOHOLIC HEPATITIS MARKET - SWOT ANALYSIS

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

18 ALCOHOLIC HEPATITIS MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Alcoholic Hepatitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/A998C8954640EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A998C8954640EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

